JP5579720B2 - ベータ−セクレターゼ調節物質としてのスピロ四環式化合物および使用法 - Google Patents

ベータ−セクレターゼ調節物質としてのスピロ四環式化合物および使用法

Info

Publication number
JP5579720B2
JP5579720B2 JP2011527012A JP2011527012A JP5579720B2 JP 5579720 B2 JP5579720 B2 JP 5579720B2 JP 2011527012 A JP2011527012 A JP 2011527012A JP 2011527012 A JP2011527012 A JP 2011527012A JP 5579720 B2 JP5579720 B2 JP 5579720B2
Authority
JP
Japan
Prior art keywords
spiro
oxazole
alkyl
amine
xanthene
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2011527012A
Other languages
English (en)
Japanese (ja)
Other versions
JP2012502112A (ja
JP2012502112A5 (enExample
Inventor
ホワイト,ライアン
アメガジエ,アルバート
ブライアン,マリアン・シー
チエン,ジエン・ジエイ
チヨン,アラン・シー
デイニーン,トーマス
エプスタイン,オレグ
ゴアー,ビジエイ・ケシヤブ
ホワ,ズーハオ
ヒユーマン,ジエイソン・ビー
ホワン,ホンビン
クレイマン,チヤールズ
ラ,ダニエル
リウ,チンイアン
マー,ブー・バン
マークス,アイザツク
パテル,ビノツド・エフ
チエン,ウエンユエン
ワイス,マシユー
ユエン,チエスター・シー
Original Assignee
アムジエン・インコーポレーテツド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by アムジエン・インコーポレーテツド filed Critical アムジエン・インコーポレーテツド
Publication of JP2012502112A publication Critical patent/JP2012502112A/ja
Publication of JP2012502112A5 publication Critical patent/JP2012502112A5/ja
Application granted granted Critical
Publication of JP5579720B2 publication Critical patent/JP5579720B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D498/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/10Spiro-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42Oxazoles
    • A61K31/424Oxazoles condensed with heterocyclic ring systems, e.g. clavulanic acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D513/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/10Spiro-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biomedical Technology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
JP2011527012A 2008-09-11 2009-09-11 ベータ−セクレターゼ調節物質としてのスピロ四環式化合物および使用法 Expired - Fee Related JP5579720B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US9608208P 2008-09-11 2008-09-11
US61/096,082 2008-09-11
PCT/US2009/056748 WO2010030954A1 (en) 2008-09-11 2009-09-11 Spiro-tetracyclic ring compounds as betasecretase modulators and methods of use

Publications (3)

Publication Number Publication Date
JP2012502112A JP2012502112A (ja) 2012-01-26
JP2012502112A5 JP2012502112A5 (enExample) 2014-07-10
JP5579720B2 true JP5579720B2 (ja) 2014-08-27

Family

ID=41319591

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2011527012A Expired - Fee Related JP5579720B2 (ja) 2008-09-11 2009-09-11 ベータ−セクレターゼ調節物質としてのスピロ四環式化合物および使用法

Country Status (21)

Country Link
US (1) US8426447B2 (enExample)
EP (1) EP2328903B1 (enExample)
JP (1) JP5579720B2 (enExample)
KR (1) KR20110073511A (enExample)
CN (1) CN102209721A (enExample)
AU (1) AU2009291602B2 (enExample)
BR (1) BRPI0918449A2 (enExample)
CA (1) CA2736130C (enExample)
CL (1) CL2011000516A1 (enExample)
CO (1) CO6362014A2 (enExample)
CR (1) CR20110134A (enExample)
EA (1) EA201100461A1 (enExample)
ES (1) ES2459195T3 (enExample)
IL (1) IL211440A0 (enExample)
MA (1) MA32705B1 (enExample)
MX (1) MX2011002705A (enExample)
MY (1) MY148558A (enExample)
PE (1) PE20110805A1 (enExample)
TW (1) TWI385175B (enExample)
WO (1) WO2010030954A1 (enExample)
ZA (1) ZA201102674B (enExample)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7763609B2 (en) 2003-12-15 2010-07-27 Schering Corporation Heterocyclic aspartyl protease inhibitors
KR101908255B1 (ko) 2009-03-13 2018-10-15 비타이 파마슈티컬즈, 인코포레이티드 베타세크리타아제 저해제
UA108363C2 (uk) 2009-10-08 2015-04-27 Похідні імінотіадіазиндіоксиду як інгібітори bace, композиція на їх основі і їх застосування
JP5828848B2 (ja) 2010-02-24 2015-12-09 ヴァイティー ファーマシューティカルズ,インコーポレイテッド ベータセクレターゼインヒビター
WO2011115938A1 (en) 2010-03-15 2011-09-22 Amgen Inc. Spiro-tetracyclic ring compounds as beta - secretase modulators
AU2011227501B9 (en) 2010-03-15 2013-08-22 Amgen Inc. Amino -dihydrooxazine and amino - dihydrothiazine spiro compounds as Beta - secretase modulators and their medical use
WO2011130741A1 (en) * 2010-04-16 2011-10-20 Array Biopharma Inc. Compounds for treating neurodegenerative diseases
WO2012019056A1 (en) * 2010-08-05 2012-02-09 Amgen Inc. Amino-iso-indole, amino-aza-iso-indole, amino-dihydroisoquinoline and amino-benzoxazine compounds as beta-secretase modulators and methods of use
WO2012027261A1 (en) 2010-08-23 2012-03-01 Amgen Inc. Sulfonylpiperazine derivatives that interact with glucokinase regulatory protein for the treatment of diabetes
US20120157448A1 (en) * 2010-11-22 2012-06-21 Adam Cook Compounds for treating neurodegenerative diseases
CN103221407A (zh) 2010-11-22 2013-07-24 出光兴产株式会社 含氧稠环衍生物和含有其而成的有机电致发光元件
WO2012071279A1 (en) * 2010-11-23 2012-05-31 Amgen Inc. Spiro-amino-imidazolone and spiro-amino-dihydro-pyrimidinone compounds as beta-secretase modulators and methods of use
US8415483B2 (en) 2010-12-22 2013-04-09 Astrazeneca Ab Compounds and their use as BACE inhibitors
US9346827B2 (en) 2011-02-07 2016-05-24 Amgen Inc. 5-amino-oxazepine and 5-amino-thiazepane compounds as beta secretase antagonists and methods of use
EP2675810A1 (en) 2011-02-15 2013-12-25 Amgen Inc. Spiro-amino-imidazo-fused heterocyclic compounds as beta-secretase modulators and methods of use
WO2012138734A1 (en) 2011-04-07 2012-10-11 Merck Sharp & Dohme Corp. C5-c6 oxacyclic-fused thiadiazine dioxide compounds as bace inhibitors, compositions, and their use
US9145426B2 (en) 2011-04-07 2015-09-29 Merck Sharp & Dohme Corp. Pyrrolidine-fused thiadiazine dioxide compounds as BACE inhibitors, compositions, and their use
MX2013014007A (es) 2011-06-07 2014-03-12 Hoffmann La Roche [1,3] oxazinas.
KR20140054295A (ko) 2011-08-22 2014-05-08 머크 샤프 앤드 돔 코포레이션 Bace 억제제로서의 2-스피로-치환된 이미노티아진 및 그의 모노- 및 디옥시드, 조성물 및 그의 용도
US9296759B2 (en) 2011-09-21 2016-03-29 Amgen Inc. Amino-oxazine and amino-dihydrothiazine compounds as beta-secretase modulators and methods of use
US9650336B2 (en) 2011-10-10 2017-05-16 Astrazeneca Ab Mono-fluoro beta-secretase inhibitors
TWI557112B (zh) 2012-03-05 2016-11-11 百靈佳殷格翰國際股份有限公司 β-分泌酶抑制劑
EP2650284A1 (en) * 2012-04-10 2013-10-16 Merz Pharma GmbH & Co. KGaA Heterocyclic derivatives as metabotropic glutamate receptor modulators
HK1208817A1 (en) * 2012-05-30 2016-03-18 Comentis, Inc. Chromane compounds
US9000184B2 (en) 2012-06-20 2015-04-07 Astrazeneca Ab Cyclohexane-1,2′-naphthalene-1′,2″-imidazol compounds and their use as BACE inhibitors
US9000183B2 (en) 2012-06-20 2015-04-07 Astrazeneca Ab Cyclohexane-1,2′-indene-1′,2″-imidazol compounds and their use as BACE inhibitors
US9000185B2 (en) 2012-06-20 2015-04-07 Astrazeneca Ab Cycloalkyl ether compounds and their use as BACE inhibitors
US9000182B2 (en) 2012-06-20 2015-04-07 Astrazeneca Ab 2H-imidazol-4-amine compounds and their use as BACE inhibitors
US10548882B2 (en) 2012-06-21 2020-02-04 Astrazeneca Ab Camsylate salt
TW201422592A (zh) 2012-08-27 2014-06-16 Boehringer Ingelheim Int β-分泌酶抑制劑
US9290477B2 (en) 2012-09-28 2016-03-22 Vitae Pharmaceuticals, Inc. Inhibitors of β-secretase
WO2014078314A1 (en) * 2012-11-15 2014-05-22 Amgen Inc. Amino-oxazine and amino-dihydrothiazine compounds as beta-secretase modulators and methods of use
WO2016126726A1 (en) 2015-02-02 2016-08-11 Forma Therapeutics, Inc. Bicyclic [4,6,0] hydroxamic acids as hdac6 inhibitors
WO2016126721A1 (en) 2015-02-02 2016-08-11 Forma Therapeutics, Inc. 3-aryl-bicyclic [4,5,0] hydroxamic acids as hdac inhibitors
EP3472131B1 (en) 2016-06-17 2020-02-19 Forma Therapeutics, Inc. 2-spiro-5- and 6-hydroxamic acid indanes as hdac inhibitors
DE102023106829A1 (de) 2023-03-19 2024-09-19 List Technology Ag Verfahren und Vorrichtung zur Behandlung eines Ausgangsproduktes

Family Cites Families (76)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2683718A (en) * 1952-01-11 1954-07-13 Searle & Co Spiro-[xanthene-9, 4'-imidazolidine]-2, 5-dione
US3185696A (en) * 1959-03-12 1965-05-25 Jack M Tien 3', 6'-diaminofluoran derivatives of gamma-lactam
FR2576178B1 (fr) 1985-01-24 1987-04-17 Furodet Philippe Procede de fabrication pour un enfumoir a chargement par-dessous
DE3601492A1 (de) 1986-01-20 1987-07-23 Vacuumschmelze Gmbh Verfahren zur herstellung eines stabilisierten filament-supraleiters mit hohem anteil an stabilisierungsmaterial
US5441870A (en) * 1992-04-15 1995-08-15 Athena Neurosciences, Inc. Methods for monitoring cellular processing of β-amyloid precursor protein
SI9300303A (en) * 1993-06-08 1994-12-31 Krka Tovarna Zdravil Process for isolation of hypolipemic effective substance
AU6383396A (en) * 1995-06-07 1996-12-30 Athena Neurosciences, Inc. Beta-secretase, antibodies to beta-secretase, and assays for detecting beta-secretase inhibition
KR20070013361A (ko) * 1998-09-24 2007-01-30 파마시아 앤드 업존 캄파니 엘엘씨 알츠하이머병 세크레타제
MY138097A (en) 2000-03-22 2009-04-30 Du Pont Insecticidal anthranilamides
JP2004502665A (ja) * 2000-06-30 2004-01-29 イーラン ファーマスーティカルズ、インコーポレイテッド アルツハイマー病を治療する化合物
US7196163B2 (en) 2001-05-22 2007-03-27 Merk & Co., Inc. Assays using amyloid precursor proteins with modified β-secretase cleavage sites to monitor β-secretase activity
WO2003002122A1 (en) * 2001-06-27 2003-01-09 Elan Pharmaceuticals, Inc. Beta-hydroxyamine derivatives useful in treatment of alzheimer's disease
KR100713137B1 (ko) 2001-06-28 2007-05-02 동화약품공업주식회사 신규의 2,4-디플루오로벤즈아미드 유도체
CA2453447A1 (en) * 2001-07-10 2003-01-23 Elan Pharmaceuticals, Inc. Alpha-hydroxyamide statine derivatives for the treatment of alzheimer's disease
WO2003006013A1 (en) * 2001-07-10 2003-01-23 Elan Pharmaceuticals, Inc. Diaminediols for the treatment of alzheimer's disease
US20030109559A1 (en) * 2001-07-11 2003-06-12 Andrea Gailunas N-(3-amino-2-hydroxy-propyl)substituted alkylamide compounds
US7244755B2 (en) * 2001-10-04 2007-07-17 Pharmacia & Upjohn Company Hydroxypropylamines
JP2005508940A (ja) 2001-10-05 2005-04-07 イーラン ファーマスーティカルズ、インコーポレイテッド アルツハイマー病の治療に有用なアリルアミド
US20050038019A1 (en) * 2001-10-29 2005-02-17 Beck James P. Hydroxy substituted amides for the treatment of alzheimer's disease
RS50504A (sr) * 2001-11-08 2007-04-10 Elan Pharmaceuticals Inc., Derivati n,n'-supstituisanog-1,3- diamino-2-hidroksipropana
AR037460A1 (es) * 2001-11-30 2004-11-10 Smithkline Beecham Plc Compuesto de hidroxietileno, composicion farmaceutica que lo comprende, uso del mismo para la fabricacion de un medicamento y procedimiento para su preparacion
MXPA04005428A (es) * 2001-12-06 2004-12-06 Elan Pharm Inc Hidroxietilaminas substituidas.
JP2005534614A (ja) * 2002-01-04 2005-11-17 イーラン ファーマスーティカルズ、インコーポレイテッド アルツハイマー病治療のための置換アミノカルボキサミド
CN1627944A (zh) * 2002-01-17 2005-06-15 神经能质公司 取代的喹唑啉-4-基胺类似物作为辣椒辣素调节剂
AU2003276047A1 (en) * 2002-06-17 2003-12-31 Sunesis Pharmaceuticals, Inc. Aspartyl protease inhibitors
US7115652B2 (en) * 2002-06-17 2006-10-03 Sunesis Pharmaceuticals, Inc. Aspartyl protease inhibitors
DE60315664D1 (de) 2002-06-20 2007-09-27 Pharmacia & Upjohn Co Llc Verfahren zur herstellung von 5-(1,3-oxazol-2-yl)benzoesäurederivaten
UY27967A1 (es) * 2002-09-10 2004-05-31 Pfizer Acetil 2-hindroxi-1,3-diaminoalcanos
EP1562897B1 (en) * 2002-11-12 2009-09-16 Merck & Co., Inc. Phenylcarboxamide beta-secretase inhibitors for the treatment of alzheimer s disease
GB0228410D0 (en) * 2002-12-05 2003-01-08 Glaxo Group Ltd Novel Compounds
AU2004204692B2 (en) * 2003-01-07 2009-07-09 Merck & Co., Inc. Macrocyclic beta-secretase inhibitors for treatment of Alzheimer's disease
EP1605940A1 (en) * 2003-03-14 2005-12-21 Merck Sharp & Dohme Ltd. METHOD FOR TREATING MILD COGNITIVE IMPAIRMENT AND FOR PREVENTING OR DELAYING ALZHEIMER’S DISEASE
GB0305918D0 (en) * 2003-03-14 2003-04-23 Glaxo Group Ltd Novel compounds
MXPA05011150A (es) * 2003-04-21 2005-12-14 Elan Pharm Inc 2-hidroxi-3-diaminoalcanos de benzamida.
CA2522805A1 (en) * 2003-04-21 2004-11-04 Elan Pharmaceuticals, Inc. Phenacyl 2-hydroxy-3-diaminoalkanes
JP2007516207A (ja) * 2003-06-30 2007-06-21 メルク エンド カムパニー インコーポレーテッド アルツハイマー病の治療のためのN−アルキルフェニルカルボキサミドβ−セクレターゼ阻害剤
US7348448B2 (en) * 2003-07-01 2008-03-25 Merck & Co., Inc. Phenylcarboxylate beta-secretase inhibitors for the treatment of alzheimer's disease
US7763609B2 (en) 2003-12-15 2010-07-27 Schering Corporation Heterocyclic aspartyl protease inhibitors
US7700603B2 (en) * 2003-12-15 2010-04-20 Schering Corporation Heterocyclic aspartyl protease inhibitors
US7592348B2 (en) * 2003-12-15 2009-09-22 Schering Corporation Heterocyclic aspartyl protease inhibitors
EP2335701B1 (en) 2003-12-15 2012-07-11 Schering Corporation Heterocyclic aspartyl protease inhibitors
GB0402143D0 (en) 2004-01-30 2004-03-03 Smithkline Beecham Corp Novel compounds
CA2561267A1 (en) 2004-03-30 2005-10-20 Merck & Co., Inc. 2-aminothiazole compounds useful as aspartyl protease inhibitors
ES2332659T3 (es) * 2004-06-16 2010-02-10 Wyeth Derivados de amino-5,5-difenilimidazolona para la inhibicion de beta-secretasa.
US20090221579A1 (en) 2004-10-15 2009-09-03 Jeffrey Scott Albert Substituted Amino-Compounds and Uses Thereof
CN101103034A (zh) 2005-01-14 2008-01-09 惠氏公司 抑制β-分泌酶的氨基-咪唑酮
US7759337B2 (en) 2005-03-03 2010-07-20 Amgen Inc. Phthalazine compounds and methods of use
CA2610828A1 (en) 2005-06-14 2006-12-28 Schering Corporation Heterocyclic aspartyl protease inhibitors, preparation and use thereof
AR054618A1 (es) 2005-06-14 2007-07-04 Schering Corp Compuestos de azetidina y su uso como inhibidores de proteasas
RU2008101667A (ru) * 2005-06-16 2009-07-27 Янссен Фармацевтика Н.В. (Be) Трициклические модуляторы опиоидов
TW200738683A (en) * 2005-06-30 2007-10-16 Wyeth Corp Amino-5-(5-membered)heteroarylimidazolone compounds and the use thereof for β-secretase modulation
US20070020316A1 (en) * 2005-07-13 2007-01-25 Raviv Laor Personal topical disinfectant device
US8211904B2 (en) 2005-07-18 2012-07-03 Merck, Sharp & Dohme Corp. Spiropiperidine beta-secretase inhibitors for the treatment of alzheimer's disease
TW200730523A (en) * 2005-07-29 2007-08-16 Wyeth Corp Cycloalkyl amino-hydantoin compounds and use thereof for β-secretase modulation
KR20080050430A (ko) 2005-09-26 2008-06-05 와이어쓰 베타-세크레타제 (bace) 억제제로서아미노-5-[4-(디플루오로메톡시)페닐]-5-페닐이미다졸론화합물
EP2612854B1 (en) * 2005-10-25 2015-04-29 Shionogi&Co., Ltd. Aminothiazolidine and aminotetrahydrothiazepine derivatives as BACE 1 inhibitors
WO2007100536A1 (en) * 2006-02-24 2007-09-07 Wyeth DIHYDROSPIRO[DIBENZO[A,D][7]ANNULENE-5,4'-IMIDAZOL] COMPOUNDS FOR THE INHIBITION OF β-SECRETASE
JP2009532464A (ja) 2006-04-05 2009-09-10 アストラゼネカ・アクチエボラーグ 2−アミノピリミジン−4−オン及びAβ−関連の病理を治療又は予防するためのその使用
TW200808751A (en) 2006-04-13 2008-02-16 Astrazeneca Ab New compounds
EP2032542A2 (en) * 2006-06-12 2009-03-11 Schering Corporation Heterocyclic aspartyl protease inhibitors
TW200815447A (en) 2006-06-14 2008-04-01 Astrazeneca Ab Novel compounds IV
TW200815349A (en) 2006-06-22 2008-04-01 Astrazeneca Ab New compounds
ATE538651T1 (de) 2006-10-30 2012-01-15 Merck Sharp & Dohme Spiropiperidininhibitoren von beta-secretase zur behandlung von alzheimer-krankheit
TW200831091A (en) 2006-12-20 2008-08-01 Astrazeneca Ab New compounds
TW200831484A (en) 2006-12-20 2008-08-01 Astrazeneca Ab New compounds
ES2510546T3 (es) 2007-02-02 2014-10-21 F. Hoffmann-La Roche Ag Nuevas 2-aminooxazolinas como ligandos TAAR1 para trastornos del SNC
CL2008000791A1 (es) 2007-03-23 2008-05-30 Wyeth Corp Compuestos derivados de 2-amino-5-(4-difluorometoxi-fenil)-5-fenil-imidazolidin-4-ona; composicion farmaceutica que comprende a dichos compuestos; y su uso en el tratamiento de una enfermedad asociada con la actividad bace excesiva, tales como enferm
TW200902526A (en) * 2007-04-24 2009-01-16 Shionogi & Amp Co Ltd Aminodihydrothiazin derivative substituted with a cyclic group
WO2008133273A1 (ja) * 2007-04-24 2008-11-06 Shionogi & Co., Ltd. アルツハイマー症治療用医薬組成物
TW200902503A (en) 2007-05-15 2009-01-16 Astrazeneca Ab New compounds
ES2548774T3 (es) * 2008-01-18 2015-10-20 Eisai R&D Management Co., Ltd. Derivado de aminodihidrotiazina condensado
CA2712228C (en) * 2008-02-18 2013-04-16 F. Hoffmann-La Roche Ag 4,5-dihydro-oxazol-2-yl amine derivatives
CL2009000954A1 (es) 2008-04-22 2010-12-31 Schering Corp Compuestos derivados de 2-imino-3-metil pirrolo pirimidinona,inhibidores de bace-1; composicion farmaceutica; y su uso para tratar, prevenir y/o retardar el inicio de una patologia de beta-amiloide seleccionada de enfermedad de alzheimer, enfermedad de parkinson, perdida de la memoria, sindrome de down, entre otras.
TWI431004B (zh) 2008-05-02 2014-03-21 Lilly Co Eli Bace抑制劑
AU2009273324A1 (en) 2008-07-24 2010-01-28 F. Hoffmann-La Roche Ag 4,5-dihydro-oxazol-2-yl derivatives
CN102105475B (zh) * 2008-07-28 2014-04-09 卫材R&D管理有限公司 螺氨基二氢噻嗪衍生物

Also Published As

Publication number Publication date
CN102209721A (zh) 2011-10-05
IL211440A0 (en) 2011-05-31
US20100087429A1 (en) 2010-04-08
EP2328903A1 (en) 2011-06-08
MA32705B1 (fr) 2011-10-02
JP2012502112A (ja) 2012-01-26
EP2328903B1 (en) 2014-03-05
KR20110073511A (ko) 2011-06-29
MX2011002705A (es) 2011-09-09
ES2459195T3 (es) 2014-05-08
AU2009291602B2 (en) 2013-02-14
CR20110134A (es) 2011-08-04
CA2736130C (en) 2014-01-14
BRPI0918449A2 (pt) 2019-09-24
ZA201102674B (en) 2011-12-28
TW201022280A (en) 2010-06-16
CO6362014A2 (es) 2012-01-20
MY148558A (en) 2013-04-30
TWI385175B (zh) 2013-02-11
CL2011000516A1 (es) 2011-08-26
PE20110805A1 (es) 2011-11-09
WO2010030954A1 (en) 2010-03-18
EA201100461A1 (ru) 2011-10-31
CA2736130A1 (en) 2010-03-18
US8426447B2 (en) 2013-04-23
AU2009291602A1 (en) 2010-03-18

Similar Documents

Publication Publication Date Title
JP2012502112A (ja) ベータ−セクレターゼ調節物質としてのスピロ四環式化合物および使用法
US8883782B2 (en) Spiro-tetracyclic ring compounds as beta-secretase modulators and methods of use
JP5584352B2 (ja) β−セクレターゼ調節剤としてのアミノ−ジヒドロオキサジン系およびアミノ−ジヒドロチアジン系スピロ化合物ならびにそれらの医学的用途
EP2601197B1 (en) Amino-iso-indole, amino-aza-iso-indole, amino-dihydroisoquinoline and amino-benzoxazine compounds as beta-secretase modulators and methods of use
EP2526092B1 (en) Amino heteroaryl compounds as beta-secretase modulators and methods of use
JP2014526560A (ja) β‐セクレターゼ調節因子としてのアミノオキサジン化合物およびアミノジヒドロチアジン化合物および使用方法
WO2012109165A1 (en) 5-amino-oxazepine and 5-amino-thiazepane compounds as beta-secretase antagonists and methods of use
JP5274258B2 (ja) β−セクレターゼ調節物質及び使用方法

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20120831

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20140116

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20140121

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20140418

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20140425

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20140520

A524 Written submission of copy of amendment under article 19 pct

Free format text: JAPANESE INTERMEDIATE CODE: A524

Effective date: 20140520

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20140610

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20140709

R150 Certificate of patent or registration of utility model

Ref document number: 5579720

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

LAPS Cancellation because of no payment of annual fees